EMERYVILLE, Calif. ( TheStreet) -- Onyx Pharmaceuticals (ONXX) is acquiring privately held cancer drugmaker Proteolix in an all-cash deal that adds a mid-stage blood cancer drug to the company's portfolio.
Under terms of the agreement, Onyx will pay $276 million upfront for Proteolix. Another $575 million in payments from Onyx to Proteolix's shareholders are contingent on the future development and success of Proteolix's lead multiple myeloma drug, carfilzomib, the company said Monday.
Wall Street has been waiting with mixed feelings for Onyx to acquire another cancer drugmaker ever since the company raised about $300 million in August. Onyx's reliance on its partnership with the German drug giant Bayer and the cancer drug Nexavar for its sole source of profit is widely seen by investors as a liability. But investors also have worried about Onyx's ability to pull off a smart acquisition that would deepen its product portfolio without overpaying.
Onyx shares are down 21% year to date.By buying Proteolix, Onyx CEO Tony Coles may have successfully threaded the needle of investor expectations. Proteolix is a private company, but its main drug carfilzomib is fairly well-known to biotech investors and analysts. Data from phase II studies presented at medical meetings last December and again in June showed the drug to be a potentially strong competitor to two well-established multiple myeloma drugs - Takeda's Velcade and Celgene's (CELG) Revlimid. The structure of the transaction is back-end loaded, so Onyx doesn't have to pay a significant portion of the $851 million total purchase price if carfilzomib's development falters.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV